The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

orbustherapeutics.com

Executives

3

Board of Directors

2

Orbus Therapeutics Board of Directors

2 Board of directors

Orbus Therapeutics has 2 board of directors, including Kurt Emster.

Name

Firm

Work History

Other Seats

Kurt Emster

Kurt joined Abingworth in January 2015, and brings 30 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies Jasper, Orbus, SFJ Pharmaceuticals, Tizona Therapeutics, Vaxcyte and Vera Therapeutics. In addition, he is on the board of CymaBay. Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.

Orbus Therapeutics

Patrick Enright

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Boehringer Mannheim (acquired by Roche), and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of Aptinyx (APTX), CuraSen Therapeutics, Dascena, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics, Rivus Pharmaceuticals, Vera Therapeutics (VERA), as well as the National Venture Capital Association (NVCA). Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé Health Science), Codexis (CDXS), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Threshold Pharmaceuticals (THLD), and Vaxcyte (PCVX). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.

Orbus Therapeutics

Name

Kurt Emster

Patrick Enright

Firm

Work History

Kurt joined Abingworth in January 2015, and brings 30 years of experience in life science investment in both private and public companies. He holds board positions at the Abingworth portfolio companies Jasper, Orbus, SFJ Pharmaceuticals, Tizona Therapeutics, Vaxcyte and Vera Therapeutics. In addition, he is on the board of CymaBay. Kurt began his career as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. He then became a General Partner at MPM Capital. In 2009, he co-founded venBio, a US healthcare investment firm and most recently was a Partner in the San Francisco office. Kurt holds a Bachelor of Arts in Business and Economics. He is based in Menlo Park.

Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Boehringer Mannheim (acquired by Roche), and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of Aptinyx (APTX), CuraSen Therapeutics, Dascena, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics, Rivus Pharmaceuticals, Vera Therapeutics (VERA), as well as the National Venture Capital Association (NVCA). Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé Health Science), Codexis (CDXS), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Threshold Pharmaceuticals (THLD), and Vaxcyte (PCVX). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.

Other Seats

Orbus Therapeutics

Orbus Therapeutics

Orbus Therapeutics Management Team

3 Team Members

Orbus Therapeutics has 3 executives. Orbus Therapeutics's current Founder, Chief Operating Officer is Jason D Levin.

Name

Work History

Title

Status

Jason D Levin

Founder, Chief Operating Officer

Current

Bob Myers

Founder, Chief Executive Officer, President

Current

Robert M Myers

Chief Executive Officer

Current

Name

Jason D Levin

Bob Myers

Robert M Myers

Work History

Title

Founder, Chief Operating Officer

Founder, Chief Executive Officer, President

Chief Executive Officer

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.